Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function. RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons). CONCLUSIONS: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TZDs have a high durability of glycemic response, most likely through a potent effect on preserving b -cell function (196).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study examined the impact of lifestyle and medications in a young cohort with diabetes duration of less than a year and found glycaemia to be best managed by the combination of rosiglitazone and metformin, with the addition of lifestyle to metformin being no better than metformin alone161.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [161]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationUse and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Research works printed but not linked: 3
- 10.1210/jc.82.7.2108 · doi:10.1210/jc.82.7.2108 · Paper page
- Harris SB, 2004, Can Fam Physician, 50, 425
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
Cited by
Items 901–1,000 of 1,014
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 61
The Role of NLRP3 Inflammasome in Pneumococcal Infections
Surabhi, S., Cuypers, F., Hammerschmidt, S., & Siemens, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.614801 · Cited by 50
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Rosiglitazone: A Review of its Use in Type 2 Diabetes Mellitus
Deeks, E. D., & Keam, S. J. (2007) · Drugs · doi:10.2165/00003495-200767180-00008 · Cited by 48
Standl, E., Erbach, M., & Schnell, O. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0353-y · Cited by 44
Oral Antihyperglycemic Treatment Options for Type 2 Diabetes Mellitus
Brietzke, S. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.012 · Cited by 49
Raskin, P. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2403 · Cited by 51
Long-term glycaemic outcome of structured nurse-led diabetes care in rural Africa
Price, C., Shandu, D., Dedicoat, M., Wilkinson, D., & Gill, G. V. (2011) · QJM · doi:10.1093/qjmed/hcr005 · Cited by 33
Blanchard, P.-G., Turcotte, V., Côté, M.-P., Gélinas, Y., Nilsson, S. K., Olivecrona, G., Deshaies, Y., & Festuccia, W. T. (2016) · Acta Physiologica · doi:10.1111/apha.12665 · Cited by 42
Pallisgaard, J. L., Lindhardt, T. B., Staerk, L., Olesen, J. B., Torp-Pedersen, C., Hansen, M. L., & Gislason, G. H. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw036 · Cited by 40
Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?
Marrano, N., Biondi, G., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154304 · Cited by 41
Via, M. A. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s9575 · Cited by 46
Changing the Treatment Paradigm for Type 2 Diabetes
Prato, S. D., Penno, G., & Miccoli, R. (2009) · Diabetes Care · doi:10.2337/dc09-s314 · Cited by 47
McGill, J. B. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.1998 · Cited by 43
Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?
Haneda, M., & Morikawa, A. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn616 · Cited by 45
Balancing Risk and Benefit with Oral Hypoglycemic Drugs
Hamnvik, O. R., & McMahon, G. T. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20116 · Cited by 49
Maeda, T., & Kishioka, S. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)85013-7 · Cited by 44
Rosiglitazone and Cardiovascular Risk
Bracken, M. B. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071602 · Cited by 45
Alvarez, C., Lingvay, I., Vuylsteke, V., Koffarnus, R. L., & McGuire, D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.143 · Cited by 46
Gomis, R., Owens, D. R., Taskinen, M., Prato, S. D., Patel, S., Pivovarova, A., Schlosser, A., & Woerle, H. J. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02975.x · Cited by 42
Ji, L., Zhang, P., Weng, J., Lu, J., Guo, X., Jia, W., Yang, W., Zou, D., Zhou, Z., Pan, C., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0054 · Cited by 42
Bianchi, E., Carrington, P. E., Ingallinella, P., Finotto, M., Santoprete, A., Petrov, A., Eiermann, G. J., Kosinski, J. R., Marsh, D. J., Pocai, A., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.016 · Cited by 46
Tajima, N., Kadowaki, T., Odawara, M., Nishii, M., Taniguchi, T., & Ferreira, J. C. A. (2011) · Diabetology International · doi:10.1007/s13340-011-0022-2 · Cited by 45
Diabetes care targets in older persons
Abbatecola, A. M., & Paolisso, G. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(09)70007-5 · Cited by 43
Home, P., Åhrén, B., Reusch, J. E. B., Rendell, M., Weissman, P. N., Cirkel, D. T., Miller, D. M., Ambery, P., Carr, M. C., & Nauck, M. A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.06.013 · Cited by 45
The Role of Alpha-Glucosidase Inhibitors (Acarbose)
Hanefeld, M., & Schäper, F. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_13 · Cited by 49
Ziyadeh, N. J., McAfee, A. T., Koro, C. E., Landon, J. E., & Chan, K. A. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.003 · Cited by 44
Wei, W., Motoike, T., Krzeszinski, J. Y., Jin, Z., Xie, X., Dechow, P. C., Yanagisawa, M., & Wan, Y. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.016 · Cited by 41
Kahn, S. E., Haffner, S. M., Viberti, G. C., Herman, W. H., Lachin, J. M., Kravitz, B. G., Yu, D., Paul, G., Holman, R. R., Zinman, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-1661 · Cited by 45
Self-citationThe molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation
Wilensky, R. L., & Hamamdzic, D. (2007) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3282f028fe · Cited by 42
Kumar, B. R. P., Baig, N. B. R., Sudhir, S., V, Kar, K., Mandava, K., Pankaj, M., & Nanjan, M. J. (2012) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2012.08.002 · Cited by 41
Feng, P., Yu, D.-M., Chen, L.-M., Chang, B.-C., Ji, Q.-D., Li, S.-Y., Zhu, M., Ding, S.-H., Zhang, B.-Z., Wang, S.-L., et al. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.136 · Cited by 41
Russell-Jones, D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02465.x · Cited by 40
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials
Mocellin, S., Pilati, P., Briarava, M., & Nitti, D. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv318 · Cited by 42
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Waldrop, G. E., Zhong, J., Peters, M. C., Goud, A., Chen, Y., Davis, S. N., Mukherjee, B., & Rajagopalan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.08.018 · Cited by 41
Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia
Bailey, C. J. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12906 · Cited by 40
Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes
Bianchi, C., Daniele, G., Dardano, A., Miccoli, R., & Prato, S. D. (2017) · Drugs · doi:10.1007/s40265-017-0694-4 · Cited by 48
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2017.12.003 · Cited by 47
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Gnesin, F., Metzendorf, M., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368.pub2 · Cited by 57
Nirwan, N., & Vohora, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.944323 · Cited by 41
Ing, S. W., & Belury, M. A. (2011) · Nutrition Reviews · doi:10.1111/j.1753-4887.2011.00376.x · Cited by 45
Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
Riche, D. M., East, H. E., & Riche, K. D. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31818eb721 · Cited by 44
Cobitz, A. R., Zambanini, A., Sowell, M. O., Heise, M. A., Louridas, B., McMorn, S. O., Semigran, M. J., & Koch, G. G. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1615 · Cited by 42
Self-citationBacon, S., Kyithar, M. P., Schmid, J., Rizvi, S. R., Bonner, C., Graf, R., Prehn, J. H. M., & Byrne, M. M. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-13 · Cited by 47
Bonora, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01441.x · Cited by 43
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Leahy, J. L. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70285-2 · Cited by 40
Defining the Role of Repaglinide in the Management of Type 2 Diabetes Mellitus: A Review
Johansen, O. E., & Birkeland, K. I. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707050-00002 · Cited by 47
GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin
Ouyang, J., Isnard, S., Lin, J., Fombuena, B., Peng, X., Chen, Y., & Routy, J.-P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.581839 · Cited by 39
Zhao, X., Zhang, X., Pei, J., Liu, Y., Niu, W., & Sun, H. (2023) · Diabetologia · doi:10.1007/s00125-023-05985-6 · Cited by 41
Lee, J., Lee, J. H., Jin, M., Han, S.-D., Chon, G.-R., Kim, I., Kim, S., Kim, S. Y., Choi, S.-B., & Noh, Y. (2014) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.52 · Cited by 41
Initiating Basal Insulin Therapy in Type 2 Diabetes: Practical Steps to Optimize Glycemic Control
Philis‐Tsimikas, A. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.010 · Cited by 42
Optimal management of type 2 diabetes: the evidence
Colagiuri, S. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01506.x · Cited by 43
The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors
Morales, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.11.2508 · Cited by 39
Williams‐Herman, D., Xu, L., Teng, R., Golm, G. T., JOHNSON, J. R., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01492.x · Cited by 43
Del Prato, S., Foley, J. E., Kothny, W., Kozlovski, P., Stumvoll, M., Paldánius, P. M., & Matthews, D. R. (2014) · Diabetic Medicine · doi:10.1111/dme.12508 · Cited by 39
Henderson, D. C., Fan, X., Sharma, B., Copeland, P. M., Borba, C. P., Boxill, R., Freudenreich, O., Cather, C., Evins, A. E., & Goff, D. C. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01325.x · Cited by 39
Clar, C., Royle, P., & Waugh, N. R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006112 · Cited by 44
Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes
Best, J. D., Drury, P., Davis, T. M. E., Taskinen, M., Kesäniemi, Y. A., Scott, R. S., Pardy, C. J., Voysey, M., KEECH, A. C., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1307 · Cited by 45
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
Wilding, J. P. H., Rajeev, S. P., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dcs15-3005 · Cited by 43
Abdul-Ghani, M., Migahid, O., Megahed, A., Adams, J., Triplitt, C., DeFronzo, R. A., Zirie, M., & Jayyousi, A. (2017) · Diabetes Care · doi:10.2337/dc16-1738 · Cited by 39
Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health?
Ko, K. D., Kim, K. K., & Lee, K. R. (2017) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2017.26.2.102 · Cited by 45
Utzschneider, K. M., Tripputi, M. T., Kozedub, A., Barengolts, E., Caprio, S., Cree‐Green, M., Edelstein, S. L., ghormli, L. K. E., Hannon, T. S., Mather, K. J., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108948 · Cited by 39
Weight Considerations in Pharmacotherapy for Type 2 Diabetes
Cheng, V., & Kashyap, S. R. (2010) · Journal of Obesity · doi:10.1155/2011/984245 · Cited by 46
Hernández, A. V., Walker, E., Ioannidis, J. P. A., & Kattan, M. W. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.03.002 · Cited by 40
Thiazolidinediones and Cardiovascular Risk — A Question of Balance
Erdmann, E., Charbonnel, B. H., & Wilcox, R. (2009) · Current Cardiology Reviews · doi:10.2174/157340309788970333 · Cited by 46
Scheen, A. J., Tan, M. H., Betteridge, D. J., Birkeland, K. I., Schmitz, O., Charbonnel, B. H., & on behalf of the PROactive investigators (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02816.x · Cited by 44
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Spectrum · doi:10.2337/diaspect.22.1.6 · Cited by 41
Self-citationRidderstråle, M., Svärd, R., Zeller, C., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-129 · Cited by 41
Ruiter, R., Visser, L. E., van Herk‐Sukel, M. P. P., Geelhoed-Duijvestijn, P. H. L. M., de Bie, S., Straus, S. M. J. M., Mol, P. G. M., Romio, S., Herings, R. M. C., & Stricker, B. H. C. (2012) · Drug Safety · doi:10.2165/11596950-000000000-00000 · Cited by 44
Safety of Antidiabetic Therapies on Bone
Lecka‐Czernik, B. (2012) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-012-9129-7 · Cited by 43
Greevy, R. A., Huizinga, M. M., Roumie, C. L., Grijalva, C. G., Murff, H., Liu, X., & Griffin, M. R. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.228 · Cited by 37
Clinical Approaches to Preserve β-Cell Function in Diabetes
WAJCHENBERG, B. L. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_23 · Cited by 41
Alhadramy, M. S. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.02.001 · Cited by 55
Hou, W., Chang, K., Li, C., & Ou, H. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13636 · Cited by 42
STAT3 dictates β-cell apoptosis by modulating PTEN in streptozocin-induced hyperglycemia
Weng, Q., Zhao, M., Zheng, J., Yang, L., Xu, Z., Zhang, Z., Wang, J., Wang, J., Yang, B., Lu, Q. R., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0344-3 · Cited by 41
Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism
Verhaegen, A. A., & Gaal, L. F. V. (2019) · Europe PMC (PubMed Central) · Cited by 53
SGLT inhibitors as antidiabetic agents: a comprehensive review
Kshirsagar, R. P., Kulkarni, A. A., Chouthe, R. S., Pathan, S. K., Une, H. D., Reddy, G. B., Diwan, P. V., Ansari, S. A., & Sangshetti, J. N. (2020) · RSC Advances · doi:10.1039/c9ra08706k · Cited by 45
The forgotten type 2 diabetes mellitus medicine: rosiglitazone
Xu, B., Xing, A., & Li, S. (2021) · Diabetology International · doi:10.1007/s13340-021-00519-0 · Cited by 43
Zhang, C.-Y., Sun, A.-J., Zhang, S.-N., Wu, C.-N., Fu, M.-Q., Xia, G., Wang, K.-Q., Zou, Y.-Z., & Ge, J.-B. (2010) · Annals of Medicine · doi:10.3109/07853891003796752 · Cited by 37
Elderly and drugs: risks and necessity of rational use
Baldoni, A. O., Chequer, F. M. D., Ferraz, E. R. A., de Oliveira, D. P., Pereira, L. R. L., & Dorta, D. J. (2010) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502010000400003 · Cited by 39
Yoon, K., Shin, J. A., Kwon, H., Lee, S., Min, K. W., Ahn, Y., Yoo, S. J., Ahn, K. J., Park, S. W., Lee, K. W., et al. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.1.26 · Cited by 43
Activation of the cAMP-PKA pathway Antagonizes Metformin Suppression of Hepatic Glucose Production
He, L., Chang, E., Peng, J., An, H., McMillin, S. M., Radovick, S., Stratakis, C. A., & Wondisford, F. E. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.719666 · Cited by 39
Thiazolidinedione Therapy Gets Complicated
Schwartz, A. V., & Sellmeyer, D. E. (2007) · Diabetes Care · doi:10.2337/dc07-0554 · Cited by 38
Nicolucci, A., & Rossi, M. C. (2008) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · Cited by 45
Wang, P., Huang, R., Lu, S., Xia, W., Sun, H., Sun, J. L., Cai, R., & Wang, S. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0285-1 · Cited by 46
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 42
White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573564 · Cited by 40
The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes
Tschöpe, D., Hanefeld, M., Meier, J. J., Gitt, A. K., Halle, M., Bramlage, P., & Schumm‐Draeger, P. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-62 · Cited by 41
Lundby‐Christensen, L., Tarnow, L., Boesgaard, T. W., Lund, S. S., Wiinberg, N., Perrild, H., Krarup, T., Snorgaard, O., Gade-Rasmussen, B., Thorsteinsson, B., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-008376 · Cited by 42
Inoue, H., Tamaki, Y., Kashihara, Y., Muraki, S., Kakara, M., Hirota, T., & Ieiri, I. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13807 · Cited by 43
Celestina, S. K., Sundaram, K., & Ravi, S. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103640 · Cited by 37
Human islet amyloid polypeptide: A therapeutic target for the management of type 2 diabetes mellitus
Roham, P. H., Save, S. N., & Sharma, S. (2022) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2022.04.001 · Cited by 38
Bray, G. A., Smith, S. R., Banerji, M. A., Tripathy, D., Clement, S. C., Buchanan, T. A., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Musi, N., et al. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12099 · Cited by 37
Petrică, L., Petrica, M., Vlad, A., Jianu, D. C., Gluhovschi, G., Ianculescu, C., Dumitraşcu, V., Giju, S., Gluhovschi, C. A., Bob, F. R., et al. (2009) · Wiener klinische Wochenschrift · doi:10.1007/s00508-009-1279-3 · Cited by 40
Clusters provide a better holistic view of type 2 diabetes than simple clinical features
Ahlqvist, E., Tuomilehto, J., & Groop, L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30257-8 · Cited by 40
A structural mechanism of nuclear receptor biased agonism
Nemetchek, M. D., Chrisman, I. M., Rayl, M. L., Voss, A. H., & Hughes, T. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215333119 · Cited by 34
Youth-onset Type 2 Diabetes: An Overview of Pathophysiology, Prognosis, Prevention and Management
Titmuss, A., Korula, S., Wicklow, B. A., & Nadeau, K. J. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01546-2 · Cited by 47
Brunton, S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12675 · Cited by 45
Type 2 Diabetes: An Expanded View of Pathophysiology and Therapy
Unger, J., & Parkin, C. G. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2152 · Cited by 42
Jalaludin, M. Y., Deeb, A., Zeitler, P., Garcia, R., Newfield, R. S., Samoilova, Y., Rosario, C. A., Shehadeh, N., Saha, C. K., Zhang, Y., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13282 · Cited by 31
Metadata
- Authors
- Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., & Viberti, G.
- Affiliations
- University of Washington (US)
- The University of Texas at San Antonio Health Science Center (US)
- GlaxoSmithKline (United States) (US)
- University of Michigan (US)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- George Washington University (US)
- Mount Sinai Hospital (CA)
- University of London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-12-07
- Volume
- 355
- Issue
- 23
- Pages
- 2427-2443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081276121
- Cited by
- 2,962
- References
- 37
- Citations by year
- 2026: 48 · 2025: 64 · 2024: 77 · 2023: 66 · 2022: 88 · 2021: 98 · 2020: 120 · 2019: 102 · 2018: 120 · 2017: 139 · 2016: 163 · 2015: 158 · 2014: 181 · 2013: 202 · 2012: 180
- FWCI
- 163.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, rosiglitazone, metformin, glibenclamide, thiazolidinediones, glycemic control, fasting blood glucose, HbA1c, insulin sensitivity, beta-cell function, cardiovascular events, congestive heart failure, hypoglycemia, weight gain, edema, gastrointestinal adverse effects, drug selection
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glyburide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Cholesterol, LDL, Male, Metformin, Middle Aged, Weight Gain, Proportional Hazards Models, Treatment Outcome, Thiazolidinediones, Waist-Hip Ratio, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.